Advertisement
Advertisement
U.S. Markets close in 6 hrs 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

Skye Bioscience, Inc. (SKYE)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0780-0.0010 (-1.27%)
As of 03:47PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0790
Open0.0780
BidN/A x N/A
AskN/A x N/A
Day's Range0.0701 - 0.0819
52 Week Range0.0250 - 0.2590
Volume1,264,252
Avg. Volume2,148,020
Market Cap27.301M
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Skye Bioscience Sponsored Research Presented at American Association of Pharmaceutical Scientists Meeting PharmSci 360

    SAN DIEGO, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today researchers from the University of Mississippi presented two Skye-sponsored studies at the 2021 American Association of Pharmaceutical Scientists Meeting (AAPS) PharmSci 360 held October 17-20, 2021, in Philadelphi

  • GlobeNewswire

    Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

    Exclusive sponsored research agreement with endocannabinoid research pioneersSAN DIEGO, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive sponsored research agreement with Emerald Health Biotechnology Espana SLU (“EHBE”), focused on developing and characterizing n

  • GlobeNewswire

    Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development

    SAN DIEGO, CA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, has strengthened its management team with the appointment of Rhea Williams, MPH, as Head of Regulatory Affairs & Quality Assurance and Varun Khurana, PhD, as Senior Director of Research & Development. Rhea Williams, MPH, brings over 25 years of experience in drug development,

Advertisement
Advertisement